(Q37991382)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22397459%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

title

Genetic and non-genetic factors affecting the response to clopidogrel therapy (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22397459%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

1 reference

Marta Karaźniewicz-Łada

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22397459%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Dorota Danielak

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22397459%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

Franciszek Główka

3

0 references

language of work or name

English

0 references

publication date

7 March 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22397459%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Pharmacotherapy

25 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22397459%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22397459%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22397459%20AND%20SRC:MED&resulttype=core&format=json

25 January 2020

page(s)

663-683

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22397459%20AND%20SRC:MED&resulttype=core&format=json

P2Y12, a new platelet ADP receptor, target of clopidogrel

25 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Platelet function monitoring in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Pharmacogenomics of clopidogrel: evidence and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

The pharmacogenetics and pharmacodynamics of clopidogrel response: an analysis from the PRINC (Plavix Response in Coronary Intervention) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Impact of cytochrome P450 2C19 loss-of-function polymorphism and of major demographic characteristics on residual platelet function after loading and maintenance treatment with clopidogrel in patients undergoing elective coronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Relation of genetic polymorphisms in the cytochrome P450 gene with clopidogrel resistance after drug-eluting stent implantation in Koreans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Association of cytochrome P450 2C19*2 polymorphism with clopidogrel response variability and cardiovascular events in Koreans treated with drug-eluting stents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Cilostazol attenuates on-treatment platelet reactivity in patients with CYP2C19 loss of function alleles receiving dual antiplatelet therapy: a genetic substudy of the CILON-T randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Common sequence variations in the P2Y12 and CYP3A5 genes do not explain the variability in the inhibitory effects of clopidogrel therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

High loading dose of clopidogrel is unable to satisfactorily inhibit platelet reactivity in patients with glycoprotein IIIA gene polymorphism: a genetic substudy of PRAGUE-8 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Clopidogrel-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Pharmacodynamic effects of concomitant versus staggered clopidogrel and omeprazole intake: results of a prospective randomized crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

A population-based study of the drug interaction between proton pump inhibitors and clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Calcium-channel blockers reduce the antiplatelet effect of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Clopidogrel resistance: role of body mass and concomitant medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Potentiation of clopidogrel active metabolite formation by rifampicin leads to greater P2Y12 receptor blockade and inhibition of platelet aggregation after clopidogrel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet thera

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Antithrombotic therapy in patients with coronary artery disease and with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Clopidogrel reduces platelet-leucocyte aggregation, monocyte activation and RANTES secretion in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Comparison of platelet reactivity and periprocedural outcomes in patients with versus without diabetes mellitus and treated with clopidogrel and percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Enhanced post-clopidogrel platelet reactivity in diabetic patients is independently related to plasma fibrinogen level but not to glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Renal function and outcomes in acute coronary syndrome: impact of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISM

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Insulin resistance as a determinant of platelet activation in obese women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: Do we need more aggressive dosing regimens in unstable angina?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox".

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Smoking, clopidogrel, and mortality in patients with established cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

The association of cigarette smoking with enhanced platelet inhibition by clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Interaction between cigarette smoking and clinical benefit of clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the Global Registry of Acute Coronary Events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Clinical overview of promising nonthienopyridine antiplatelet agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive Summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention—Summary Article

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524

Impact of adjunctive cilostazol therapy on platelet function profiles in patients with and without diabetes mellitus on aspirin and clopidogrel therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2012.666524